CONTENTS

List of Tables in Text ........................................ xii
List of Tables in Appendices ............................... xv
Preface .......................................................... xvi
How to Use This Book .................................... xviii
How to Use StudyWare™ to Accompany
Pharmacological Aspects of Nursing Care,
7th Edition .................................................. xxii
NCLEX-PN and NCLEX-RN Test Plans ............. xxx

SECTION 1
Introduction to Drugs and Drug Administration

CHAPTER 1
Drugs/Agents and Factors Affecting
Their Action ................................................. 2
History ......................................................... 3
Sources of Drug .......................................... 4
Drug Uses .................................................... 4
Dosage Forms ............................................. 5
Drug Names ................................................ 9
Classification of Drugs .................................. 10
Canadian Drug Legislation .............................. 16
Drug Information Resources ............................ 16
The Product Insert ....................................... 17
Principles of Drug Action ................................ 19
Adverse Drug Effects .................................... 20
Pharmacokinetic Factors in Drug Therapy ...... 21
Monitoring Drug Therapy ............................... 25
Individual Variation of Pharmacological
Response .................................................. 26
Drug Interactions ......................................... 27
Physical and Chemical Incompatibilities ......... 27
Herbals and Botanical Medicine .................... 27

CHAPTER 2
Principles and Methods of Drug
Administration ............................................. 37
The Nursing Process and Medication
Administration ............................................. 37
Administering Medications ............................. 39
Nursing Process in Client Teaching ................ 63
Fostering Compliance and Cooperation with
Medication Regimens .................................. 66
Nursing Process Approach to Improving
Cooperation ................................................ 68

CHAPTER 3
Intravenous Drug Therapy ............................. 73
Intravenous Infusion Therapy ........................ 74
Applying the Nursing Process ....................... 79
Electronic Infusion Devices ......................... 86

CHAPTER 4
Calculating Medication Dosages ................. 95
Interpreting the Drug Prescriptions .......... 95
Ratio and Proportion ..................................... 96
Conversion between Systems of Measurement 99
Calculation of Fractional Doses ..................... 102
Calculation of Dosages Based on Weight ...... 103
Pediatric Dosage Calculations ....................... 104
Calculations Involving Intravenous
Administration .......................................... 105
Calculations Related to Solutions ................ 108
Prevention of Medication Errors .................. 109

CHAPTER 5
Drug Therapy for Pediatric Clients ........... 112
Pediatric Drug Therapy ............................... 112
Applying the Nursing Process ..................... 116
Nursing Children Receiving Medications .... 116
Poisoning .................................................... 125
Herbals ....................................................... 126

CHAPTER 6
Drug Therapy for Geriatric Clients ........... 131
Geriatric Drug Therapy ............................... 131
Applying the Nursing Process ..................... 134
Nursing Care of Elderly Clients Receiving
Drug Therapy ............................................ 134

SECTION 2
Agents That Interfere with
Microbial Growth

CHAPTER 7
Antimicrobial Agents ................................. 144
Susceptibility of the Body to Infection .......... 144
Sources of Infection ..................................... 146
Identification of the Infecting Organism ....... 148
Selection of Antimicrobial Agents ............... 148
Classification of Antimicrobial Agents ......... 150
Adverse Effects .......................................... 151
Antibacterial Agents .................................. 152
Urinary Tract Anti-Infectives ....................... 178
Drugs Used to Treat Tuberculosis ............... 180
Drugs Used to Treat Lyme Disease .......... 181
Antifungal Drugs ....................................... 183
Antiviral Drugs .......................................... 186
Miscellaneous Anti-Infective Agents .......... 195
CONTENTS

CHAPTER 3: Agents Used to Control Pain and Inflammation

CHAPTER 10: Analgesics and Antipyretics 258
- Pain 258
- Opioid Analgesics 261
- Opioid Agonists 269
- Opioid Antagonists 270
- Nonopioid Analgesics 270
- Analgesic Antipyretics 271
Applying the Nursing Process 279
- Nonopioid Analgesics 282
- Opioid Analgesics 284
- Opioid Drugs and the Law 285
- Client-Controlled Analgesia 286
- Client-Controlled Oral Analgesia 287
- Control of Chronic Pain 288
- Pain Management in End-of-Life Care 290
Nursing Care Plan: A Client Receiving Morphine Sulfate Following Appendectomy 292
Nursing Care Plan: A Client Receiving Morphine via Epidural Catheter Following Hysterectomy 294

CHAPTER 11: Anesthetics 301
- Anesthesia 301
- Regional Anesthesia 308
Applying the Nursing Process 314
- Clients with Malignant Hyperthermia 316
Nursing Care Following General Anesthesia 317
- Safety and Anesthetic Agents 318
Nursing Care Following Regional (Local) Anesthesia 318
- Overall Assessment 319
Nursing Care Plan: A Postsurgical Client 320

CHAPTER 12: Anti-Inflammatory Agents 325
- Nonsteroidal Anti-Inflammatory Drugs 326
- Disease-Modifying Antirheumatic Drugs 330
- Slow- Acting Antirheumatic Agents 332
- Corticosteroids 333
Applying the Nursing Process 340
- Clients Receiving Nonsteroidal Anti-Inflammatory Agents 340

CONTENTS

Clients Receiving Drug-Modifying Antirheumatic Drugs ............... 342
Clients Receiving Slow-Acting Antirheumatic Drugs ............... 343
Clients Receiving Corticosteroids ......................... 344
Nursing Care Plan: A Client with Arthritis Taking Adalimumab and Prednisone .... 346

CHAPTER 13
Agents Used to Treat Hyperuricemia and Gout ...................... 352
Management of Acute Gouty Arthritis .................. 353
Control of Hyperuricemia ....................... 355
Applying the Nursing Process ..................... 356
Nursing Care Plan: A Client with Hyperuricemia and Gout Taking Probenecid and Colchicine ............... 358

SECTION 4
Agents Used to Treat Respiratory Disorders

CHAPTER 14
Antihistamines and Nasal Decongestants ....................... 364
Antihistamines .................. 365
Decongestants ................ 366
Applying the Nursing Process ..................... 373
Nursing Care Plan: A Client with a Cold Taking Pseudoephedrine Hydrochloride (Sudafed) ............... 376

CHAPTER 15
Expectorant and Antitussive Agents .................... 382
Expectorants .................. 382
Antitussives ................ 383
Applying the Nursing Process ..................... 383
Nursing Care Plan: A Child with Bronchitis Taking Guaifenesin (Robitussin) Syrup ............... 388

CHAPTER 16
Bronchodilators and Other Respiratory Agents ............. 393
Bronchodilators .................. 393
Mucolytics .................. 400
Mast Cell Stabilizers ................... 400
Applying the Nursing Process ..................... 402
Nursing Care Plan: A Client with Asthma Using Cromolyn Sodium (Intal) and Terbutaline Sulfate (Brethine) ............... 406

SECTION 5
Agents Used to Treat Cardiovascular Disorders

CHAPTER 17
Cardiac Stimulants and Depressants .................. 414
Cardiac Glycosides .................. 416
Inamrinone Lactate (Inamrinone) and Milrinone Lactate (Primacor) ............... 419
Antiarrhythmic/Antidysrhythmic Agents ............... 419
Cardiac Stimulants Used to Treat Shock ............... 428
Applying the Nursing Process ..................... 431
Clients Receiving Cardiac Glycosides ............... 431
Clients Receiving Antidysrhythmic Agents ............... 434
Clients in Cardiac Emergencies and Shock ............... 435
Nursing Care Plan: An Insulin-Dependent Client with Cardiac Antidysrhythmia Taking Amiodarone Hydrochloride (Cordarone) ............... 436

CHAPTER 18
Agents That Dilate Blood Vessels .................... 442
Coronary Vasodilators .................. 442
Myocardial Infarction ............... 447
Peripheral Vasodilators ............... 450
Applying the Nursing Process ..................... 450
Clients Receiving Coronary Vasodilators ............... 450
Clients Receiving Peripheral Vasodilators ............... 454
Nursing Care Plan: A Client with Angina Using Transdermal Nitroglycerin (Nitro-Dur) ............... 455

CHAPTER 19
Agents Affecting Blood Clotting .................... 461
Anticoagulants .................. 461
Antiplatelet Agents ............... 467
Thrombolytic Agents ............... 468
Tissue Plasminogen Activator ............... 469
Hemorheologic Agents ............... 469
Hemostatic Agents ............... 469
Applying the Nursing Process ............... 470
Clients Receiving Anticoagulants ............... 470
Comfort and Safety ............... 472
Client Education ............... 474
Nursing Care Following Intracoronary Thrombolysis ............... 475
Nursing Care Plan: A Client with Acute Myocardial Infarction Receiving Alteplase (Activase), A Tissue Plasminogen Activator ............... 477

CHAPTER 20
Diuretics and Antihypertensives .................... 482
Diuretics .................. 482
CONTENTS

Antihypertensive Agents . 488
Applying the Nursing Process . 501
  Meeting Sodium and Potassium Needs . 502
  Long-Term Client Management . 505
  Management of Hypertensive Emergencies . 507
Nursing Care Plan: A Client with Hypertension
  Taking Enalapril Maleate (Vasotec),
  Hydrochlorothiazide . 508

CHAPTER 21
Agents Used in the Treatment of Hyperlipidemia . 514
Hyperlipidemia . 514
Applying the Nursing Process . 519
Nursing Care Plan: A Client with Hyperlipidemia Receiving Simvastatin (Zocor) . 520

CHAPTER 22
Agents Used to Treat Anemias . 526
Iron Deficiency Anemia . 527
Megaloblastic Anemias . 529
Applying the Nursing Process . 532
Nursing Care Plan: A Client with Crohn’s Disease Taking Vitamin B12 . 534

CHAPTER 23
Vitamins, Minerals, and Other Nutritional Agents . 539
Protein . 540
Fat . 543
Carbohydrate . 544
Vitamins . 544
Minerals . 547
Total Parenteral Nutrition . 552
Applying the Nursing Process . 553
Nursing Care Plan: A Client with Congestive Heart Failure Receiving a Diuretic with a Potassium Supplement . 556

SECTION 6
Agents Used to Treat Gastrointestinal Disorders

CHAPTER 24
Agents Used to Treat Hyperacidity and Gastroesophageal Reflux Disease . 564
Antacids . 565
Histamine H₂ Receptor Antagonists . 569
Proton Pump Inhibitors . 570
Sucralfate (Carafate) . 571
Misoprostol (Cytotec) . 571
Metoclopramide (Reglan, Emex) . 571
Gastrointestinal Enzymes . 572
Applying the Nursing Process . 572
  Nursing Clients Taking Antacids . 572
  Nursing Clients Receiving Histamine H₂ Receptor Antagonists, Proton Pump Inhibitors, and Sucralfate . 575
  Nursing Clients Taking Metoclopramide . 576
Nursing Care Plan: A Client with Peptic Ulcer Disease Taking Antacids . 578
Nursing Care Plan: A Client with Hiatal Hernia Taking Metoclopramide (Reglan) and Esomeprazole Magnesium (Nexium) . 580

CHAPTER 25
Emetics and Antiemetics . 585
Emetics . 585
Antiemetics . 586
Applying the Nursing Process . 590
  Clients Taking Emetics . 590
  Clients Taking Antiemetics . 591

CHAPTER 26
Laxatives and Antidiarrheals . 596
Laxatives . 596
Antidiarrheal Agents . 602
Applying the Nursing Process . 604
  Clients Receiving Laxatives . 604
  Clients Receiving Antidiarrheal Agents . 607

SECTION 7
Agents Affecting the Nervous System

CHAPTER 27
Central Nervous System Sedatives and Hypnotics . 614
Barbiturates . 614
Benzodiazepines . 617
Nonbenzodiazepines . 619
Alcohol (Ethanol) . 620
Other Sedative-Hypnotics . 620
Applying the Nursing Process . 622
  Clients Receiving Sedative-Hypnotics . 622
  Clients Receiving Barbiturates . 623
  Clients Receiving Nonbarbiturates . 624
Nursing Care Plan: A Client with Anxiety Taking Diazepam (Valium) . 627

CHAPTER 28
Anxiolytics and Other Agents Used to Treat Psychiatric Conditions . 632
Antianxiety Agents (Anxiolytics) . 632
Agents Used to Treat Affective Disorders 638
Antidepressant Agents 638
Antipsychotic Agents 643
Antimanic Agents 645
Applying the Nursing Process 648
Clients Receiving Drug Therapy for Anxiety and/or Psychiatric Conditions 648
Clients Receiving Anxiolytics 650
Clients Receiving Antidepressants 651
Clients Receiving Antipsychotic Agents 653
Clients Receiving Antimanic Agents 657
Nursing Care Plan: A Client with Bipolar Illness Taking Lithium Carbonate 658

CHAPTER 29
Agents Used to Treat Attention-Deficit Hyperactivity Disorder and Alzheimer’s Disease 665
Anorexiant 666
Atomoxetine Hydrochloride (Strattera) 666
Analeptics 668
Agents Used to Treat Alzheimer’s Disease 668
Applying the Nursing Process 671
Clients Receiving Central Nervous System Stimulants 671
Clients Receiving Medications to Treat Alzheimer’s Disease 673
Nursing Care Plan: A Child with Attention-Deficit Hyperactivity Disorder Taking Atomoxetine Hydrochloride (Strattera) 674

CHAPTER 30
Agents Used in Musculoskeletal Disorders 679
Neuromuscular Blocking Agents 680
Centrally Acting Skeletal Muscle Relaxants 682
Direct-Acting Skeletal Muscle Relaxants 685
Skeletal Muscle Stimulants 685
Applying the Nursing Process 688
Clients Taking Neuromuscular Blocking Agents 688
Clients Taking Centrally Acting Skeletal Muscle Relaxants 689
Clients Taking Direct-Acting Skeletal Muscle Relaxants 690
Clients Taking Skeletal Muscle Stimulants 691
Nursing Care Plan: A Client with Myasthenia Gravis Taking Pyridostigmine Bromide (Mestinon) and Receiving Edrophonium Chloride (Tensilon, Reversol) 692

CHAPTER 31
Anti-Parkinson Agents 697
Dopaminergic Agents 698
Anticholinergic Agents 700
Catechol-O-Methyltransferase Inhibitors 704
Applying the Nursing Process 704
Nursing Care Plan: A Client with Parkinson’s Disease Taking Carbidopa-Levodopa (Sinemet) 706

CHAPTER 32
Anticonvulsants 712
Applying the Nursing Process 731
Nursing Care Plan: A Child with Epilepsy Taking Phenytoin (Dilantin) and Phenobarbital 738

CHAPTER 33
Substance Abuse 743
Opiate Abuse 745
Central Nervous System Depressant Abuse 748
Central Nervous System Stimulants 752
Cannabis Abuse 753
Psychedelic Agents 754
“Ecstasy” 755
Tobacco 755
Inhalant Abuse 757
Applying the Nursing Process 760
Screening for Substance Abuse 760
Nursing Care for Substance Abuse 761
Nursing Care during Detoxification 762
Treatment of Substance Abuse 763
Impaired Health Care Workers 763
Establishing a Drug-Free Workplace 764
Substance Abuse Education 764
Nursing Care Plan: A Client with Substance Abuse Receiving Naloxone Hydrochloride (Narcan) 766

CHAPTER 34
Autonomic Nervous System 770
The Sympathetic Nervous System 771
The Parasympathetic (Cholinergic) Nervous System 773
Agents That Affect the Autonomic Nervous System 774
Sympathomimetics (Adrenergics) 774
Sympatholytics (Adrenergic Blockers) 775
Parasympathomimetics (Cholinergics) 776
Parasympatholytics (Anticholinergics) 776
Antispasmodics 779
Applying the Nursing Process 781
Nursing Care Plan: A Client with an Overactive Bladder Taking Trospium Chloride (Sanctura) 783
SECTION 8
Agents Used to Correct Endocrine Imbalance

CHAPTER 35
Agents Affecting Thyroid, Parathyroid, and Pituitary Function
Thyroid Disorders
Parathyroid Disorders
Pituitary Disorders
Applying the Nursing Process
Clients Taking Thyroid Medication
Clients Taking Antithyroid Medication
Clients Taking Medication for Parathyroid Disorders
Clients Taking Pituitary Hormones
Nursing Care Plan: A Client with Diabetes Insipidus Using DDAVP Spray

CHAPTER 36
Agents Used to Treat Hyperglycemia and Hypoglycemia
Insulin Therapy
Islet Transplantation
Oral Hypoglycemic Agents
Parenteral Therapy for Type 2 Diabetes
Applying the Nursing Process
Decreasing Deficient Knowledge
Administration of Insulin by Pump
Storage and Care of Insulin and Supplies
Glucose Monitoring
Insulin Reactions and Diabetic Ketoacidosis
Safety Precautions
Nursing Care for Type 2 Diabetic Clients
Nursing Care Plan: A Client with Diabetes Insipidus Using DDAVP Spray

CHAPTER 37
Sex Hormones
Female Sex Hormones
Estrogen and Progesterone Combinations
Ovulation Stimulants
Male Sex Hormones
Impotence
Anabolic Agents
Danazol (Cyclomen, Danocrine)
Nafarelin Acetate (Synarel) and Histrelin Acetate (Vantus)
Leuprolide Acetate (Lupron Depot)
Androgen Hormone Inhibitors
Tamsulosin Hydrochloride (Flomax)
Applying the Nursing Process
Clients Taking Ovulation Stimulants
Nursing Care Plan: A Client with Endometriosis Treated with Leuprolide Acetate (Lupron Depot)
Clients Receiving Agents to Treat Erectile Dysfunction

CHAPTER 38
Agents Used in Obstetrical Care
Uterine Stimulants
Abortifacients
Uterine Relaxants
Lactation Suppressants
RhD Immune Globulin (BayRho-D, RhoGAM, MICRhoGAM, WinRho)
Applying the Nursing Process
Clients Taking Drugs That Influence Labor and Delivery
Clients Taking Abortifacients
Clients Taking Uterine Relaxants
Clients Taking Lactation Suppressants or Stimulants
Nursing Care Plan: A Pregnant Client Using Ritodrine Hydrochloride

SECTION 9
Agents Affecting the Reproductive System

CHAPTER 39
Agents That Affect Immunity
Agents That Provide Active or Passive Immunity
Interferons and Interleukins
Immunosuppressant Agents
Antiviral Agents for Human Immunodeficiency Virus
Drugs Used to Treat Gaucher’s Disease
Applying the Nursing Process
Clients Receiving Agents to Enhance the Immune System
Clients Receiving Agents to Suppress the Immune System
Nursing Care Plan: A Client Receiving Muromonab-CD3 (Orthoclone OKT 3) Following Heart Transplantation
### CHAPTER 40
Agents Used in the Treatment of Cancer ............................. 925
- Alkylating Agents ........................................... 928
- Antimetabolites ............................................. 928
- Mitotic Inhibitors .......................................... 928
- Antibiotics .................................................. 929
- Hormones .................................................... 930
- Corticosteroids ............................................ 930
- Radioactive Drugs ......................................... 930
- Biological-Response Modifiers ........................... 930
- Miscellaneous Antineoplastic Agents ................. 930
- Monoclonal Antibodies ................................... 930
- Protease Inhibitors ........................................ 930
- Combination Therapy ..................................... 931
- Adjuvant Agents ............................................ 931
- Antiemetics .................................................. 934
- Applying the Nursing Process ............................ 934
- Special Drug Delivery Methods .......................... 938
- Safe Handling of Cytotoxic Agents ..................... 963
- Nursing Care Plan: A Client Receiving Chemotherapy for Lung Cancer .......... 964
- Clients Receiving Investigational Agents .......... 967

### SECTION 11
Agents Used to Treat Eye, Ear, and Skin Disorders

### CHAPTER 41
Agents Used in the Treatment of Eye Disorders ...................... 974
- Mydriatic Agents .......................................... 974
- Ophthalmic Anti-Infectives .............................. 975
- Antiseptics .................................................. 979
- Local Anesthetics ......................................... 979
- Corticosteroids .......................................... 979
- Nonsteroidal Anti-Inflammatory Agents ............. 980
- Miscellaneous Agents .................................... 981
- Glaucoma .................................................... 981
- Agents That Decrease the Formation of Aqueous Humor .......... 982
- Agents That Increase the Outflow of Aqueous Humor .......... 984
- Agents That Decrease Formation and Increase Outflow of Aqueous Humor .......... 986
- Applying the Nursing Process .......................... 986
- Clients with Glaucoma .................................... 990
- Nursing Care Plan: A Client with an Eye Infection Using Vidarabine Ointment (Vira-A) .......... 994

### CHAPTER 42
Agents Used in the Treatment of Ear Disorders .................... 1001
- Drugs Used in Otic Therapy .............................. 1002
- Antimicrobials ............................................. 1002
- Applying the Nursing Process .......................... 1004
- Nursing Care Plan: A Client with Otitis Media Receiving Amoxicillin/Potassium Clavulanate (Augmentin) .......... 1006

### CHAPTER 43
Agents Used in the Treatment of Skin Disorders .................... 1010
- Drugs Used in Dermatological Therapy .................. 1012
- Diabetic Foot Ulcers ....................................... 1020
- Antineoplastic Agents .................................... 1020
- Agents Used to Treat Eczema ............................ 1021
- Agents Used to Treat Psoriasis .......................... 1022
- Agents Used to Treat Burns .............................. 1022
- Minoxidil (Rogaine) ...................................... 1022
- Masoprolol (Actinex) ...................................... 1022
- Applying the Nursing Process .......................... 1024
- Clients Receiving Antifungal Agents ................... 1025
- Nursing the Burn Client .................................. 1027
- Nursing Care Plan: A Child with Burns Being Treated with Silver Sulfadiazine .......... 1028

Nursing Care Plan: A Client with Glaucoma Using Pilocarpine via Ocusert Therapeutic System .......... 996

Appendix 1: Nomograms for Children and Adults .................. 1034
Appendix 2: Diagnostic Agents ................................ 1036
Appendix 3: Approximate Normal Values ..................... 1040
Appendix 4: Toxicology Overview ........................... 1043
Appendix 5: Common Food/Drug/Herbal Interactions .......... 1047
Appendix 6: Spanish and French Translations of Common Medication Instructions .......... 1062
Appendix 7: Abbreviations Commonly Found in Drug Prescriptions .......... 1065

Glossary ..................................................... 1067
References ................................................... 1087
Index .......................................................... 1089
<table>
<thead>
<tr>
<th>TABLE</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>Herbs</td>
<td>30</td>
</tr>
<tr>
<td>2-1</td>
<td>Abbreviations Commonly Found in Drug Prescriptions</td>
<td>42</td>
</tr>
<tr>
<td>2-2</td>
<td>Potentially Confusing Abbreviations, Acronyms, and Symbols: A List from the Joint Commission on Accreditation of Healthcare Organizations</td>
<td>43</td>
</tr>
<tr>
<td>2-3</td>
<td>Some Commonly Used Approximate Weight and Measure Equivalents</td>
<td>45</td>
</tr>
<tr>
<td>2-4</td>
<td>Types of Syringes in Common Use</td>
<td>47</td>
</tr>
<tr>
<td>2-5</td>
<td>Common Routes of Drug Administration</td>
<td>49</td>
</tr>
<tr>
<td>2-6</td>
<td>Administration of Oral Medications</td>
<td>53</td>
</tr>
<tr>
<td>2-7</td>
<td>Selection of Needles for Injection</td>
<td>55</td>
</tr>
<tr>
<td>3-1</td>
<td>Common Intravenous Solutions</td>
<td>75</td>
</tr>
<tr>
<td>4-1</td>
<td>Amount/Dosage</td>
<td>96</td>
</tr>
<tr>
<td>4-2</td>
<td>Preparations</td>
<td>96</td>
</tr>
<tr>
<td>4-3</td>
<td>Routes</td>
<td>97</td>
</tr>
<tr>
<td>4-4</td>
<td>Special Instructions</td>
<td>97</td>
</tr>
<tr>
<td>4-5</td>
<td>Times</td>
<td>97</td>
</tr>
<tr>
<td>4-6</td>
<td>Values of Single Roman Numbers</td>
<td>98</td>
</tr>
<tr>
<td>4-7</td>
<td>Metric Prefixes</td>
<td>99</td>
</tr>
<tr>
<td>4-8</td>
<td>Common Metric Abbreviations</td>
<td>100</td>
</tr>
<tr>
<td>4-9</td>
<td>Liquid Measure in the Apothecary System</td>
<td>101</td>
</tr>
<tr>
<td>4-10</td>
<td>Apothecary Notation</td>
<td>101</td>
</tr>
<tr>
<td>5-1</td>
<td>Classification of Pediatric Clients</td>
<td>113</td>
</tr>
<tr>
<td>5-2</td>
<td>Guidelines for the Administration of Oral and Parenteral Medications to Young Children</td>
<td>118</td>
</tr>
<tr>
<td>7-1</td>
<td>Penicillins</td>
<td>155</td>
</tr>
<tr>
<td>7-2</td>
<td>Cephalosporins</td>
<td>161</td>
</tr>
<tr>
<td>7-3</td>
<td>Tetracyclines</td>
<td>166</td>
</tr>
<tr>
<td>7-4</td>
<td>Macrolides/Erythromycins</td>
<td>167</td>
</tr>
<tr>
<td>7-5</td>
<td>Aminoglycosides</td>
<td>169</td>
</tr>
<tr>
<td>7-6</td>
<td>Fluoroquinolones</td>
<td>170</td>
</tr>
<tr>
<td>7-7</td>
<td>Other Antibacterial Agents</td>
<td>173</td>
</tr>
<tr>
<td>7-8</td>
<td>Sulfonamide Products for Systemic Use</td>
<td>179</td>
</tr>
<tr>
<td>7-9</td>
<td>Laboratory Test Interactions</td>
<td>181</td>
</tr>
<tr>
<td>7-10</td>
<td>Antitubercular Drugs</td>
<td>182</td>
</tr>
<tr>
<td>7-11</td>
<td>Antiviral Drugs</td>
<td>187</td>
</tr>
<tr>
<td>7-12</td>
<td>Antiviral Drug Interactions</td>
<td>195</td>
</tr>
<tr>
<td>8-1</td>
<td>Drugs Used in the Treatment of Malaria</td>
<td>222</td>
</tr>
<tr>
<td>8-2</td>
<td>Drugs of Choice for the Treatment of Intestinal Parasitic Worm Infestations</td>
<td>226</td>
</tr>
<tr>
<td>9-1</td>
<td>Commonly Used Antiseptics and Disinfectants</td>
<td>241</td>
</tr>
<tr>
<td>10-1</td>
<td>Receptor Activity Related to Some Analgesic Drugs</td>
<td>261</td>
</tr>
<tr>
<td>10-2</td>
<td>Opioid Analgesics</td>
<td>263</td>
</tr>
<tr>
<td>10-3</td>
<td>Equianalgesic Doses of Opioid Analgesics</td>
<td>268</td>
</tr>
<tr>
<td>10-4</td>
<td>Opioid Antagonists</td>
<td>271</td>
</tr>
<tr>
<td>10-5</td>
<td>Nonopioid Analgesics</td>
<td>272</td>
</tr>
<tr>
<td>10-6</td>
<td>Some Popular Opioid Analgesic Combination Products</td>
<td>275</td>
</tr>
<tr>
<td>10-7</td>
<td>Drug Products Used to Treat Migraine Headaches</td>
<td>276</td>
</tr>
<tr>
<td>10-8</td>
<td>Drug Products Used for Client-Controlled Analgesia</td>
<td>289</td>
</tr>
<tr>
<td>11-1</td>
<td>Changes in Body Function during Stages and Planes of Anesthesia</td>
<td>303</td>
</tr>
<tr>
<td>11-2</td>
<td>General Anesthetics Administered by Inhalation</td>
<td>305</td>
</tr>
<tr>
<td>11-3</td>
<td>General Anesthetics Administered by Injection</td>
<td>307</td>
</tr>
<tr>
<td>TABLE</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
<td>------</td>
</tr>
<tr>
<td>11-4</td>
<td>Drugs Used as Adjuncts to General Anesthesia</td>
<td>309</td>
</tr>
<tr>
<td>11-5</td>
<td>Common Types of Regional Anesthesia</td>
<td>311</td>
</tr>
<tr>
<td>11-6</td>
<td>Regional Anesthesia Agents</td>
<td>312</td>
</tr>
<tr>
<td>12-1</td>
<td>Nonsteroidal Anti-Inflammatory Agents</td>
<td>327</td>
</tr>
<tr>
<td>12-2</td>
<td>Disease-Modifying Antirheumatic Drugs</td>
<td>331</td>
</tr>
<tr>
<td>12-3</td>
<td>Slow-Acting Antirheumatic Agents</td>
<td>333</td>
</tr>
<tr>
<td>12-4</td>
<td>Corticosteroids for Systemic Use</td>
<td>335</td>
</tr>
<tr>
<td>12-5</td>
<td>Corticosteroids Administered by Local Injection</td>
<td>337</td>
</tr>
<tr>
<td>12-6</td>
<td>Corticosteroids for Topical Use</td>
<td>337</td>
</tr>
<tr>
<td>13-1</td>
<td>Drugs Used to Treat Gout</td>
<td>354</td>
</tr>
<tr>
<td>14-1</td>
<td>Antihistamines</td>
<td>368</td>
</tr>
<tr>
<td>14-2</td>
<td>Decongestants</td>
<td>370</td>
</tr>
<tr>
<td>14-3</td>
<td>Intranasal Steroid Products</td>
<td>372</td>
</tr>
<tr>
<td>15-1</td>
<td>Expectorants</td>
<td>384</td>
</tr>
<tr>
<td>15-2</td>
<td>Antitusives</td>
<td>385</td>
</tr>
<tr>
<td>16-1</td>
<td>Sympathomimetic Bronchodilators</td>
<td>395</td>
</tr>
<tr>
<td>16-2</td>
<td>Xanthine Bronchodilators</td>
<td>399</td>
</tr>
<tr>
<td>16-3</td>
<td>Corticosteroids Used by Inhalation in the Treatment of Bronchial Asthma</td>
<td>402</td>
</tr>
<tr>
<td>17-1</td>
<td>Cardiac Glycosides in Current Use</td>
<td>417</td>
</tr>
<tr>
<td>17-2</td>
<td>Antiarrhythmic Drugs</td>
<td>420</td>
</tr>
<tr>
<td>17-3</td>
<td>Antiarrhythmic/Antidysrhythmic Drugs in Current Use</td>
<td>425</td>
</tr>
<tr>
<td>17-4</td>
<td>Agents Used in the Treatment of Shock</td>
<td>430</td>
</tr>
<tr>
<td>18-1</td>
<td>Nitrates Used in the Treatment of Angina</td>
<td>445</td>
</tr>
<tr>
<td>18-2</td>
<td>Non-Nitrates Used in the Treatment of Angina Pectoris</td>
<td>447</td>
</tr>
<tr>
<td>19-1</td>
<td>Blood Clotting Factors</td>
<td>462</td>
</tr>
<tr>
<td>19-2</td>
<td>Dosage Guidelines for Administering Heparin</td>
<td>464</td>
</tr>
<tr>
<td>19-3</td>
<td>Oral Anticoagulants</td>
<td>465</td>
</tr>
<tr>
<td>20-1</td>
<td>Thiazide Diuretics</td>
<td>484</td>
</tr>
<tr>
<td>20-2</td>
<td>Nonthiazide Diuretics</td>
<td>486</td>
</tr>
<tr>
<td>20-3</td>
<td>Nondiuretic Antihypertensive Agents</td>
<td>494</td>
</tr>
<tr>
<td>21-1</td>
<td>Classes of Lipoproteins</td>
<td>515</td>
</tr>
<tr>
<td>21-2</td>
<td>Effects of Antihyperlipidemic Drugs on Serum Lipids and Lipoproteins</td>
<td>518</td>
</tr>
<tr>
<td>22-1</td>
<td>Iron Preparations</td>
<td>529</td>
</tr>
<tr>
<td>23-1</td>
<td>Comparison of Selected Nutrients in the Dietary Approaches to Stop Hypertension (DASH) Eating Plan, the USDA Food Guide, and Nutrient Intakes Recommended per Day by the Institute of Medicine (IOM)</td>
<td>542</td>
</tr>
<tr>
<td>23-2</td>
<td>Some Potassium-Rich Foods</td>
<td>549</td>
</tr>
<tr>
<td>24-1</td>
<td>Active Ingredients in Antacid Products</td>
<td>567</td>
</tr>
<tr>
<td>24-2</td>
<td>Histamine H₂ Receptor Antagonists</td>
<td>569</td>
</tr>
<tr>
<td>25-1</td>
<td>Antiemetics</td>
<td>587</td>
</tr>
<tr>
<td>26-1</td>
<td>Stimulant Laxatives</td>
<td>597</td>
</tr>
<tr>
<td>26-2</td>
<td>Saline Laxatives</td>
<td>598</td>
</tr>
<tr>
<td>26-3</td>
<td>Bulk-Forming Laxatives</td>
<td>600</td>
</tr>
<tr>
<td>26-4</td>
<td>Stool Softeners</td>
<td>601</td>
</tr>
<tr>
<td>26-5</td>
<td>Antidiarrheal Drugs That Reduce Gastrointestinal Motility</td>
<td>603</td>
</tr>
<tr>
<td>27-1</td>
<td>Barbiturates Used as Sedatives and Hypnotics</td>
<td>615</td>
</tr>
<tr>
<td>27-2</td>
<td>Benzodiazepines Used as Hypnotic Agents</td>
<td>617</td>
</tr>
<tr>
<td>27-3</td>
<td>Nonbarbiturates/Sedative-Hypnotic Agents</td>
<td>620</td>
</tr>
<tr>
<td>28-1</td>
<td>Oral Anxiolytic Agents</td>
<td>635</td>
</tr>
<tr>
<td>28-2</td>
<td>Monoamine Oxidase Inhibitors</td>
<td>639</td>
</tr>
<tr>
<td>28-3</td>
<td>Some Tyramine-Rich Foods</td>
<td>640</td>
</tr>
<tr>
<td>28-4</td>
<td>Antidepressants</td>
<td>641</td>
</tr>
</tbody>
</table>
TABLE 28-5  Antipsychotic Drugs  .............................................................. 646
29-1  Anorectic Agents  ................................................................. 666
29-2  Nonanorectic Central Nervous System Stimulants  ......................... 668
29-3  Caffeine Content of Common Beverages  ...................................... 669
30-1  Neuromuscular Blocking Agents (Intravenous)  .............................. 681
30-2  Centrally Acting Skeletal Muscle Relaxants  .................................. 683
30-3  Anticholinesterase Muscle Stimulants  ........................................ 687
31-1  Drugs Used to Treat Parkinson’s Disease  ...................................... 701
32-1  Anticonvulsants in Current Use  ................................................ 718
32-2  Drug Interactions with Common Anticonvulsants  ............................ 728
33-1  Effects of Various Blood Alcohol Concentrations on the Human Body  .... 750
33-2  Common Drugs and Symptoms of Abuse  ..................................... 757
34-1  Some Organ Responses to Autonomic Nerve Impulses  ...................... 773
34-2  Anticholinergics That Are Belladonna Derivatives  ........................... 777
34-3  Synthetic Anticholinergics Used as Antispasmodics  ......................... 780
35-1  Classification of Hyperthyroidism  ............................................ 790
35-2  Drugs Used to Treat Hyperthyroidism  ........................................ 791
35-3  Classification of Hypothyroidism  .............................................. 793
35-4  Thyroid Preparations  ............................................................. 795
35-5  Drugs Used in the Treatment of Diabetes Insipidus  ......................... 799
36-1  Insulin Preparations  ............................................................. 818
36-2  Administration of Insulins  ...................................................... 819
36-3  Insulins Commonly Used in the United States  ............................... 820
36-4  Less Commonly Used Insulins  ............................................... 821
36-5  Human and Analog Insulin: Time of Action  .................................. 821
36-6  Insulin Capabilities/Nursing Implications  .................................... 822
36-7  Stability of In-Use Insulin at Room Temperature  ............................ 823
36-8  Oral Hypoglycemic Agents  ..................................................... 824
36-9  Conversion of the A-1-C to Average Blood Sugar  ........................... 826
37-1  Estrogen Products  ............................................................... 849
37-2  Progestational Products  .......................................................... 852
37-3  Oral Contraceptive Products  .................................................... 855
37-4  Topical Contraceptives  .......................................................... 859
37-5  Androgen Products  .............................................................. 861
37-6  Anabolic Products  ............................................................... 862
39-1  Agents Used in Providing Passive Immunity  .................................. 894
39-2  Agents Used for Active Immunization  ........................................ 898
39-3  Recommended Childhood Immunization Schedule  ........................ 908
39-4  Agents Used in the Prophylaxis of Rabies  .................................... 910
40-1  Neoplastic Disorders in Which Chemotherapy Has Significantly
      Prolonged Survival  .................................................................. 927
40-2  Antineoplastic Agents’ Potential for Causing Nausea/Vomiting  ........... 931
40-3  Examples of Combination Chemotherapeutic Regimens  .................... 932
40-4  Commonly Used Anticancer Drugs  ............................................. 935
41-1  Sympathomimetic Mydriatic Drugs  ............................................. 976
41-2  Anticholinergic Mydriatic Drugs  ............................................... 977
41-3  Antimicrobials Used to Treat Eye Infections  ................................... 978
41-4  Local Anesthetics Used in the Eye  ............................................. 980
41-5  Carbonic Anhydrase Inhibitors Used in Glaucoma  .......................... 983
41-6  Osmotic Diuretics Used in Glaucoma  ......................................... 985
41-7  Direct-Acting Miotics Used in Glaucoma  ...................................... 986
41-8  Cholinesterase Inhibitors Used in Glaucoma  .................................. 987
TABLE 43-1  Dermatological Dosage Forms ................................................. 1013
43-2  Popular Emollient Products ......................................................... 1014
43-3  Popular Keratolytic Products ....................................................... 1015
43-4  Topical Local Anesthetics ............................................................. 1016
43-5  Topical Antibiotic Products .......................................................... 1017
43-6  Topical Antifungal Agents ............................................................ 1018
43-7  Topical Debriding Agents ............................................................. 1021
43-8  Topical Burn Preparations ............................................................ 1023

APPENDICES

TABLE 1  Nomograms for Children and Adults ............................................. 1034
  2A  Biological In Vivo Diagnostic Agents ............................................... 1036
  2B  In Vitro Diagnostic Agents ............................................................. 1038
  3A  Blood Values ................................................................................. 1040
  3B  Hematologic Values ...................................................................... 1041
  3C  Celsius–Fahrenheit Equivalents ...................................................... 1042
  4A  Specific Antidotes ......................................................................... 1044
  4B  Toxicology: Guidelines ................................................................. 1045
  5  Clinically Significant Drug/Food/Herbal Interactions ......................... 1048